Associated Papers
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Raal FJ et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2024
38545781 (PubMed )
Supplement: atv-44-1156-s001.pdf
OptiMo-LDLr: An Integrated In Silico Model with Enhanced Predictive Power for LDL Receptor Variants, Unraveling Hot Spot Pathogenic Residues.
Larrea-Sebal A et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2024
38258479 (PubMed )
Supplement: ADVS-11-2305177-s001.pdf
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
Pirillo A et al.
Atherosclerosis. Supplements, 2017
Molecular genetic background of an autosomal dominant hypercholesterolemia in the Czech Republic.
Tichý L et al.
Physiological Research, 2017
Nucleotide variation of sFRP5 gene is not associated with obesity in children and adolescents.
Van Camp JK et al.
Molecular Biology Reports, 2016
The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia.
Wiegman A et al.
Pediatric Research, 2003
Nephrogenic diabetes insipidus: functional analysis of new AVPR2 mutations identified in Italian families.
Albertazzi E et al.
Journal of the American Society of Nephrology : Jasn, 2000
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects.
Flavell DM et al.
Diabetologia, 2000
Select a paper to view details